Finance / United States
Ipsen To Expand Further In The US
June 2008 | In The NewsFrance's pharmaceutical company Ipsen has agreed to pay US$404mn for the remaining stake it does not already own in its US partner Tercica to gain a larger foothold in the endocrinology market. Ipsen will pay US$9 per share in cash, more than double Tercica's trading price of US$4.41 on June 4. The company currently owns a 25.5% stake in the biopharmaceutical company. The deal, which values Brisbane, California-based Terica at approximately US$663mn, won unanimous approval from Tercica's Board of
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Corporate Financing Week and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Corporate Financing Week please click on the trial link below.
Free Trial to CFW
Register here for your FREE 7-day trial to Corporate Financing Week!
TAKE A TRIAL >>
